

Clinical trials of fibroblast growth factor gene

TrialResults-center www.trialresultscenter.org

1 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
fibroblast growth factor gene vs placebo			
AGENT 3 and 4 pooled n=NA follow-up:	-	-	
AGENT-1 (Grines) , 2002 n=NA follow-up:	-	-	
AGENT-2 (Grines) , 2003 n=NA follow-up:	-	-	
AGENT-3 [NCT00346437] n=NA follow-up:	Ad5FGF-4 (replication deficient, E1A/E1Bdeleted, human adenovirus serotype 5 with human FGF-4 gene insert: alferminogene tadenovec versus placebo	-	
AGENT-4 [NCT00185263] n=NA follow-up:	Ad5FGF-4 (replication deficient, E1A/E1Bdeleted, human adenovirus serotype 5 with human FGF-4 gene insert: alferminogene tadenovec versus placebo	-	
AWARE [NCT00438867] n=NA follow-up:	intracoronary infusion of Ad5FGF-4 versus placebo	Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization	double blind

More details and results :

- cell-based therapies for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q300>

References

AGENT 3 and 4 pooled, 0:

AGENT-1 (Grines), 2002:

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL *Circulation* 2002;105:1291-7 [[11901038](#)]

AGENT-2 (Grines), 2003:

Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N *J Am Coll Cardiol* 2003;42:1339-47 [[14563572](#)]

AGENT-3, 0:

AGENT-4, 0:

AWARE, 0:

Entry terms: fibroblast growth factor